Triptorelin is a man-made decapeptide (a chain of 10 amino acids, the building blocks of proteins: pGlu-His-Trp-Ser-Tyr-D-Trp-Leu-Arg-Pro-Gly-NH2). It is a strong GnRH agonist (a drug that copies GnRH, the brain hormone that starts the reproductive hormone chain). It grips the GnRH receptor tightly and for longer than the natural hormone. After injection, triptorelin binds GnRH receptors on gonadotroph cells in the front part of the pituitary (the master hormone gland at the base of the brain) gland (a pea-sized gland at the base of the brain). At first this triggers a sharp release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), called the 'flare' phase, which lasts 1-2 weeks. With constant exposure (from depot formulations, slow-release injections), the receptors stop responding and are pulled inside the cell (desensitization and downregulation (dials down activity), caused by uncoupling of G-protein signaling and receptor internalization). The result is the opposite of the start: LH and FSH output drops. This cuts off the signal for testosterone production in Leydig cells (in men) and estrogen production in ovarian granulosa cells (in women). Testosterone falls to castration levels (<0.7 nmol/L) within 3-4 weeks in most patients, and stays low as long as the depot medicine continues to be given. Changes to the decapeptide make it resist breakdown by enzymes (proteolytic resistance) and last longer than natural GnRH. Combined with pamoate or embonate salts (esterification), this allows depot formulations given once a month (3.75mg), every 3 months (11.25mg), or every 6 months (22.5mg).